Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: Results of a randomized, placebo-controlled, phase 2 trial

Archives of Dermatology

Volumn 144, Issue 2, 2008, Pages 200-207

  Kimball, Alexa B ^a   Gordon, Kenneth B ^b   Langley, Richard G ^c   Menter, Alan ^d   Chartash, Elliot K ^e   Valdes, Joaquin ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Division of Dermatology   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

^d BAYLOR RESEARCH INSTITUTE   (United States)

^e ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 874; INTERLEUKIN 12; INTERLEUKIN 23; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS VULGARIS; RHINOPHARYNGITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; MALE; MIDDLE AGED; NASOPHARYNGITIS; PSORIASIS; RESPIRATORY TRACT INFECTIONS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 39649108216     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archdermatol.2007.63     Document Type: Article

References (32)

1. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136-139.
2. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med. 2001;345(5):340-350.
3. Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(suppl 2):ii18-ii23.
4. de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004;9(2):140-147.
5. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280-284.
6. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132(2):236-244.
7. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383-392.
8. Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol. 2004;45(3):155-159.
9. Lebwohl M, Ali S. Treatment of psoriasis, part 1: topical therapy and phototherapy. J Am Acad Dermatol. 2001;45(4):487-498.
10. Lebwohl M, Ali S. Treatment of psoriasis, part 2: systemic therapies. J Am Acad Dermatol. 2001;45(5):649-661.
11. Finlay AY, Ortonne JP. Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy. J Cutan Med Surg. 2004;8(5):310-320.
12. Anderson EJR, McGrath MA, Thalhamer T, McInnes IB. Interleukin-12 to interleukin "infinity": the rationale for future therapeutic cytokine targeting. Springer Semin Immunopathol. 2006;27(4):425-442.
13. Rosmarin D, Strober BE. The potential of interleukin 12 inhibition in the treatment of psoriasis. J Drugs Dermatol. 2005;4(3):318-325.
14. Hong K, Chu A, Ludviksson BR, Berg EL, Ehrhardt RO. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol. 1999;162(12):7480-7491.
15. Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol. 1998;111(6):1053-1057.
16. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123-1132.
17. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133-1141.
18. Lee E, Trepiccchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125-130.
19. Shaker OG, Moustafa W, Essmat S, Abdel-Halim M, El-Komy M. The role of interleukin-12 in the pathogenesis of psoriasis. Clin Biochem. 2006;39(2):119-125.
20. Piskin G, Sylva-Steenland RMR, Bos JD, Teunissen MBM. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol. 2006;176(3):1908-1915.
21. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80(2):273-290.
22. Kauffman CL, Aria N, Toichi E, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol. 2004;123(6):1037- 1044.
23. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580-592.
24. Kimball AB, Gordon KB, Valdes JM. Safety and efficacy of the fully human IL-12/23 monoclonal antibody, ABT-874, in the treatment of moderate to severe plaque psoriasis: results from a phase II trial [abstract 321]. J Invest Dermatol. 2007;127(suppl 1):S54.
25. Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244.
26. Ko H-S. Clinical trial design in psoriasis. Paper presented at: 49th Meeting of the Dermatologic and Ophthalmologic Advisory Committee; March 20, 1998; Bethesda, MD.
27. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant important endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50(6):859-866.
28. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139(12):1627-1632.
29. Reich K, Nestle FO, Papp K, et al; EXPRESS Study Investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367- 1374.
30. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598-606.
31. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE; Alefacept Clinical Study Group. An international, randomized, double-blind, placebocontrolled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139(6):719-727.
32. Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005;141(1):31-38.